| Website | nucanabiomed.com |
| Category | BioTech |
| Phone | +44 (0) 131 248 3660 |
| Employees |
| TOTAL | $10.9M |
| VENTURE FUNDING TOTAL | $10.9M |
| Series A, 11/11 Sofinnova Partners Morningside Venture Investments Scottish Venture Fund | £6.74M |
NuCana BioMed is an emerging biopharmaceutical company dedicated to the discovery, development and commercialisation of innovative, rationally designed medicines that address significant unmet medical needs. Our management team has extensive experience of building successful biopharmaceutical companies. This includes the formation and subsequent growth of Bioenvision into a NASDAQ National listed, global biopharmaceutical company, which was acquired by Genzyme Corporation in October 2007. Specific management expertise includes the development, approval and commercialisation of oncology medicines. We are developing a portfolio of first-in-class and best-in-class pharmaceutical products designed to treat life-threatening or debilitating diseases. Our primary focus is in the area of oncology, although our technology platform has broader clinical potential.
